Zhengye Biotechnology Holding Ltd (ZYBT) shareholders
ZYBTNasdaqPharmaceutical Preparations
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Apr 28, 2026Score 4/30
$1.52+0.09 (+6.29%)
Close on Nov 17, 2026Market cap $72.03MP/E –Yield –
Ownership
Who owns Zhengye Biotechnology's shares
Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Securingium Holding Limited Joint filing with TSet Holding Limited (90.66%), Trident Trust Company (HK) Limited (90.66%) and 6 more | 42,963,748 | 90.66% | 13G (passive) | Dec 31, 2024 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Songlin Song | Co-Chief Executive Officer | – | – | Jun 25, 2026 |
| Yuhong (nmn) Cheng | Vice General Manager | – | – | Jun 25, 2026 |
| Ping (nmn) Wang | Chief Financial Officer | – | – | Jun 25, 2026 |
| Aiden Han | Co-Chief Executive Officer | – | – | Mar 18, 2026 |
| Wei Lian | Vice General Manager | – | – | Mar 18, 2026 |
| Zhongyao Liu | Chief Operating Officer | – | – | Mar 18, 2026 |
| Ping (PiJi) Jiang | Director | – | – | Jun 25, 2026 |
| Zhenfa Han | Director, 10% owner | 42,963,748 | 90.66% | Jun 25, 2026 |
| Qiyi Hu | Director | – | – | Apr 24, 2026 |
| Guohan (nmn) Li | Director | – | – | Apr 24, 2026 |
| Wenhua Sun | Director | – | – | Mar 18, 2026 |
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of shares outstanding
–
0M shares short
Days to cover
1.0
At 0M shares a day
Change since last report
-53.9%
From 0M shares
Short volume, 20 days
49.6%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Zhengye Biotechnology's stock actually held short. Settlement fails (shares not delivered on time) peaked at 122,643 shares on Oct 13, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Vanguards Skyline Holdings Limited Shareholder | Oct 22, 2025 | 2,278,752 | $29.42M | Nov 1, 2025 | Purchase |
| VVAX Holdings Limited Shareholder | Oct 22, 2025 | 684,996 | $1.79M | Nov 1, 2025 | Purchase |
See a number that looks wrong?